{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:28:16Z","timestamp":1753892896963,"version":"3.41.2"},"reference-count":205,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Vaccine preventable diseases (VPDs) are a prevailing concern among the adult population, despite availability of vaccines. Unlike pediatric vaccination programs, adult vaccination programs lack the required reach, initiative, and awareness. Clinical studies and real-world data have proven that vaccines effectively reduce the disease burden of VPDs and increase life expectancy. In Tunisia and Morocco, the national immunization program (NIP) focuses more on pediatric vaccination and have limited vaccination programs for adults. However, some vaccination campaigns targeting adults are organized. For example, influenza vaccination campaigns prioritizing at risk adults which includes healthcare professionals, elderly, and patients with comorbidities. Women of childbearing age who have never been vaccinated or whose information is uncertain are recommended to receive tetanus vaccination. Tunisia NIP recommends rubella vaccine mainly for women of childbearing age, while in Morocco, national vaccination campaigns were organized for girls and women (up to 24 years of age) to eliminate rubella. Further, travelers from both countries are recommended to follow all requirements and recommendations in the travel destination. The objective of this manuscript is to provide an overview of the global disease burden of common VPDs including (but not limited to) meningococcal diseases, pneumococcal diseases, hepatitis, and influenza. The review also provides an overview of clinical data and guidelines\/recommendations on adult vaccination practices, with special focus on Tunisia and Morocco. Some European and North American countries have concrete recommendations and strategies for adult vaccination to keep the VPDs in check. In Morocco and Tunisia, although, there are sporadic adult vaccination initiatives, the efforts still need upscaling and endorsements to boost vaccination awareness and uptake. There is a need to strengthen strategies in both countries to understand the disease burden and spread awareness. Additional studies are needed to generate economic evidence to support cost-effectiveness of vaccines. Integration of private and public healthcare systems may further improve vaccination uptake in adults.<\/jats:p>","DOI":"10.3389\/fpubh.2022.903376","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T07:21:37Z","timestamp":1656660097000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco"],"prefix":"10.3389","volume":"10","author":[{"given":"Redouane","family":"Abouqal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"Beji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Chakroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Marhoum El Filali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihane","family":"Rammaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hela","family":"Zaghden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cger.2017.08.006","article-title":"Vaccinations in older adults","volume":"34","author":"Burke","year":"2018","journal-title":"Clin Geriatr Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1080\/21645515.2019.1692564","article-title":"Adult vaccination in India: status and the way forward","volume":"16","author":"Lahariya","year":"2020","journal-title":"Hum Vaccin Immunother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.4161\/21645515.2014.982998","article-title":"Adult vaccination: now is the time to realize an unfulfilled potential","volume":"11","author":"Tan","year":"2015","journal-title":"Hum Vaccin Immunother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/07853890.2019.1588470","article-title":"Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion","volume":"51","author":"Doherty","year":"2019","journal-title":"Ann Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4161\/hv.35858","article-title":"Adult vaccination","volume":"11","author":"Swanson","year":"2015","journal-title":"Hum Vaccin Immunother."},{"key":"B6","unstructured":"2019"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.vaccine.2021.01.066","article-title":"Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries","volume":"39","author":"Sauer","year":"2021","journal-title":"Vaccine."},{"key":"B8","doi-asserted-by":"publisher","first-page":"8264","DOI":"10.1016\/j.vaccine.2020.11.002","article-title":"Understanding immunosenescence and its impact on vaccination of older adults","volume":"38","author":"Allen","year":"2020","journal-title":"Vaccine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun Ageing."},{"key":"B10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41579-020-00506-3","article-title":"The role of vaccines in combatting antimicrobial resistance","volume":"19","author":"Micoli","year":"2021","journal-title":"Nat Rev Microbiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1080\/21645515.2015.1043502","article-title":"Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: capita, the community-acquired pneumonia immunization trial in adults","volume":"11","author":"Isturiz","year":"2015","journal-title":"Hum Vaccin Immunother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e2128652","DOI":"10.1001\/jamanetworkopen.2021.28652","article-title":"Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: a phase 3 randomized clinical trial","volume":"4","author":"Vesikari","year":"2021","journal-title":"J Am Med Assoc Netw Open."},{"key":"B13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.vaccine.2017.12.029","article-title":"Report on who meeting on immunization in older adults: Geneva, Switzerland, 22-23 March 2017","volume":"36","author":"Teresa Aguado","year":"2018","journal-title":"Vaccine."},{"key":"B14","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.vaccine.2015.12.052","article-title":"Burden of four vaccine preventable diseases in older adults","volume":"34","author":"Kristensen","year":"2016","journal-title":"Vaccine."},{"key":"B15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40121-021-00420-y","article-title":"The burden of invasive vaccine-preventable diseases in adults in the Middle East and North Africa (Mena) Region","volume":"10","author":"Bizri","year":"2021","journal-title":"Infect Dis Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements","volume":"59","author":"Martin\u00f3n-Torres","year":"2016","journal-title":"J Adolesc Health."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinf.2017.04.007","article-title":"Meningococcal disease in the Middle East and Africa: findings and updates from the global meningococcal initiative","volume":"75","author":"Borrow","year":"2017","journal-title":"J Infect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijid.2020.11.162","article-title":"A review of the epidemiology of invasive meningococcal disease and vaccination strategies in North Africa","volume":"104","author":"Taha","year":"2021","journal-title":"Int J Infect Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1080\/21645515.2016.1181243","article-title":"Issues in pediatric vaccine-preventable diseases in low- to middle-income countries","volume":"12","author":"Dbaibo","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"B20","unstructured":"2021"},{"key":"B21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.vaccine.2019.10.028","article-title":"Seasonal influenza vaccination in middle-income countries: assessment of immunization practices in Belarus, Morocco, and Thailand","volume":"38","author":"Mantel","year":"2020","journal-title":"Vaccine."},{"key":"B22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jpag.2015.11.002","article-title":"Knowledge of human papillomavirus and acceptability to vaccinate in adolescents and young adults of the Moroccan population","volume":"29","author":"Zouheir","year":"2016","journal-title":"J Pediatr Adolesc Gynecol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0157432","DOI":"10.1371\/journal.pone.0157432","article-title":"Prevalence, genotype distribution and risk factors for cervical human papillomavirus infection in the Grand Tunis Region, Tunisia","volume":"11","author":"Ardhaoui","year":"2016","journal-title":"PLoS ONE."},{"key":"B24","unstructured":"2021"},{"key":"B25","unstructured":"2020"},{"key":"B26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4254\/wjh.v4.i3.68","article-title":"Hepatitis A: epidemiology and prevention in developing countries","volume":"4","author":"Franco","year":"2012","journal-title":"World J Hepatol."},{"key":"B27","unstructured":"2021"},{"key":"B28","doi-asserted-by":"publisher","first-page":"518618","DOI":"10.1159\/000518618","article-title":"Prevalence of hepatitis B virus infection markers among patients of Ibn Sina University Hospital Center (Rabat, Morocco)","volume":"2021","author":"Feindiri","year":"2021","journal-title":"Intervirology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7027169","DOI":"10.1155\/2020\/7027169","article-title":"A Systematic review of the current hepatitis B viral infection and hepatocellular carcinoma situation in mediterranean countries","volume":"2020","author":"Madihi","year":"2020","journal-title":"Biomed Res Int."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckz187.076","article-title":"Prevalence and risk factors of hepatitis B in Tunisia","author":"Lahchaichi","year":"2019","journal-title":"Eur J Public Health."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1809223","DOI":"10.1080\/19932820.2020.1809223","article-title":"Hepatitis B birth vaccination, cohort study, Tunisia 2000\u20132017","volume":"15","author":"Dhouib","year":"2020","journal-title":"Libyan J Med."},{"key":"B32","unstructured":"2018"},{"key":"B33","doi-asserted-by":"publisher","first-page":"10029","DOI":"10.3390\/vetsci7010029","article-title":"Knowledge, attitudes, and practices regarding rabies in El Jadida Region, Morocco","volume":"7","author":"Bouaddi","year":"2020","journal-title":"Vet Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"105822","DOI":"10.1016\/j.actatropica.2021.105822","article-title":"Rabies in Tunisia: a spatio-temporal analysis in the region of Capbon-Nabeul","volume":"216","author":"Hassine","year":"2021","journal-title":"Acta Trop."},{"key":"B35","unstructured":"2021"},{"key":"B36","unstructured":"2021"},{"key":"B37","unstructured":"2021"},{"key":"B38","unstructured":"2020"},{"key":"B39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nri3085","article-title":"Vaccines for the twenty-first century society","volume":"11","author":"Rappuoli","year":"2011","journal-title":"Nat Rev Immunolgy."},{"key":"B40","doi-asserted-by":"publisher","first-page":"103571","DOI":"10.1016\/j.micpath.2019.103571","article-title":"Global estimate of neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis","volume":"134","author":"Purmohamad","year":"2019","journal-title":"Microb Pathog."},{"key":"B41","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health."},{"key":"B42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","article-title":"The global meningococcal initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations","volume":"18","author":"Acevedo","year":"2019","journal-title":"Expert Rev Vaccines."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1016\/j.vaccine.2015.06.046","article-title":"Prevention and control of meningococcal outbreaks: the emerging role of serogroup B meningococcal vaccines","volume":"33","author":"Oviedo-Orta","year":"2015","journal-title":"Vaccine."},{"key":"B45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1128\/JCM.00445-18","article-title":"Molecular characterization of invasive isolates of neisseria meningitidis in Casablanca, Morocco","volume":"56","author":"Razki","year":"2018","journal-title":"J Clin Microbiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijid.2021.11.036","article-title":"Implementation of a prospective study for enhancing surveillance of invasive bacterial infections in North Africa","volume":"115","author":"Smaoui","year":"2022","journal-title":"Int J Infect Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10096-002-0736-y","article-title":"Serogroups, serotypes, serosubtypes and antimicrobial susceptibility of neisseria meningitidis isolates in Casablanca, Morocco","volume":"21","author":"Zerouali","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis."},{"journal-title":"Les Infections Invasives \u00c0 Neisseria Meningitidis Chez L'enfant \u00c0 Tunis: \u00c0 Propos De 79 Cas. J Jebali, Ch Jeanneau, A Bazaa, S Mathieu, M El Ayeb.","year":"2011","author":"Smaoui","key":"B48"},{"key":"B49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.26719\/2016.22.5.343","article-title":"Characterization of invasive neisseria meningitidis strains isolated at the children's hospital of Tunis, Tunisia","volume":"22","author":"Saguer","year":"2016","journal-title":"Eastern Mediterranean Health J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/cid\/ciy800","article-title":"Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood Pcv13 immunization","volume":"68","author":"Pelton","year":"2018","journal-title":"Clin Infect Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.tmaid.2018.05.016","article-title":"Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis","volume":"24","author":"Van Aalst","year":"2018","journal-title":"Travel Med Infect Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12879-018-3326-z","article-title":"Clinical and economic burden of pneumococcal disease in us adults aged 19-64 years with chronic or immunocompromising diseases: an observational database study","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Infect Dis."},{"key":"B53","unstructured":"2020"},{"key":"B54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2018.02.008","article-title":"Proportion of adult community-acquired pneumonia cases attributable to streptococcus pneumoniae among Hajj Pilgrims in 2016","volume":"69","author":"AlBarrak","year":"2018","journal-title":"Int J Infect Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"020421","DOI":"10.7189\/jogh.09.020421","article-title":"Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the glamor project","volume":"9","author":"Paget","year":"2019","journal-title":"J Glob Health."},{"key":"B56","unstructured":"2021"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet."},{"key":"B58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(18)30496-X","article-title":"Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the global burden of disease study 2017","volume":"7","author":"GBD","year":"2019","journal-title":"Lancet Respir Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fpubh.2020.552028","article-title":"Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation","volume":"8","author":"Kombe Kombe","year":"2021","journal-title":"Front Public Health."},{"key":"B60","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00404-011-2155-8","article-title":"Prevalence and risk factors of Hpv infection among women from various provinces of the world","volume":"285","author":"Vinodhini","year":"2012","journal-title":"Arch Gynecol Obstet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J Infect Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/infdis\/jiu077","article-title":"Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual","volume":"210","author":"Moreira","year":"2014","journal-title":"Men J Infect Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1016\/j.vaccine.2012.08.058","article-title":"Monitoring of rotavirus vaccination in Morocco: establishing the baseline burden of rotavirus disease","volume":"30","author":"Benhafid","year":"2012","journal-title":"Vaccine."},{"key":"B64","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1186\/s12879-020-05318-7","article-title":"Hepatitis a virus infection in Central-West Tunisia: an age structured model of transmission and vaccination impact","volume":"20","author":"Ayouni","year":"2020","journal-title":"BMC Infect Dis."},{"key":"B65","first-page":"92","article-title":"Epidemiologic profile of hepatitis a in Mekn\u00e8s, Morocco, 2013-2016","volume":"29","author":"Essayagh","year":"2019","journal-title":"Med Sante Trop."},{"key":"B66","unstructured":"2017"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e0212853","DOI":"10.1371\/journal.pone.0212853","article-title":"Epidemiology and disease burden of tuberculosis in South of Tunisia over a 22-year period: current trends and future projections","volume":"14","author":"Ben Ayed","year":"2019","journal-title":"PLoS ONE."},{"key":"B68","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s41182-021-00388-y","article-title":"Tuberculosis in the middle of covid-19 in Morocco: efforts, challenges and recommendations","volume":"49","author":"Bouaddi","year":"2021","journal-title":"Trop Med Health."},{"key":"B69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.vaccine.2018.11.023","article-title":"Seroprevalence of pertussis among healthcare workers: a cross-sectional study from Tunisia","volume":"37","author":"Ben Fraj","year":"2019","journal-title":"Vaccine."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s40121-021-00442-6","article-title":"Bordetella pertussis in school-age children, adolescents, and adults: a systematic review of epidemiology, burden, and mortality in Africa","volume":"10","author":"Macina","year":"2021","journal-title":"Infect Dis Ther."},{"key":"B71","unstructured":"2022"},{"key":"B72","unstructured":"2019"},{"key":"B73","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40266-013-0065-0","article-title":"Immunogenicity and safety of a quadrivalent meningococcal serogroups a, C, W-135 and Y tetanus toxoid conjugate vaccine (Menacwy-Tt) administered to adults aged 56 years and older: results of an open-label, randomized, controlled trial","volume":"30","author":"Dbaibo","year":"2013","journal-title":"Drugs Aging."},{"key":"B74","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12879-015-1138-y","article-title":"Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups a, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial","volume":"15","author":"Borja-Tabora","year":"2015","journal-title":"BMC Infect Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"881","DOI":"10.4161\/hv.20212","article-title":"The investigational meningococcal serogroups a, C, W-135, Y tetanus toxoid conjugate vaccine (Acwy-Tt) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults","volume":"8","author":"Aplasca-De Los Reyes","year":"2012","journal-title":"Hum Vaccin Immunother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1016\/j.vaccine.2020.04.067","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (Menacyw-Tt) in \u226556-year-olds: a phase Iii randomized study","volume":"38","author":"Esteves-Jaramillo","year":"2020","journal-title":"Vaccine."},{"key":"B77","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","article-title":"Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (Menacyw-Tt) in adolescents and adults: a phase Iii randomized study","volume":"38","author":"Dhingra","year":"2020","journal-title":"Vaccine."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.vaccine.2016.01.044","article-title":"A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent Rlp2086 in healthy adolescents and young adults","volume":"34","author":"Ostergaard","year":"2016","journal-title":"Vaccine."},{"key":"B79","doi-asserted-by":"publisher","first-page":"402","DOI":"10.7883\/yoken.JJID.2017.277","article-title":"A safety and immunogenicity study of a single dose of a meningococcal (groups a, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine (Men-Acwy-D) in Healthy Japanese Participants","volume":"71","author":"Fukushima","year":"2018","journal-title":"Jpn J Infect Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40121-020-00393-4","article-title":"Post-marketing surveillance observational study of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menacwy-Dt, Mcv4\/Menactra(\u00ae)) in the Republic of Korea, 2014-2019","volume":"10","author":"Kim","year":"2021","journal-title":"Infect Dis Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/jtm.12180","article-title":"Immunogenicity and safety of concomitant administration of a combined hepatitis a\/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults","volume":"22","author":"Alberer","year":"2015","journal-title":"J Travel Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijid.2014.06.008","article-title":"Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (Menacwy-Crm) in healthy Korean adolescents and adults","volume":"28","author":"Lee","year":"2014","journal-title":"Int J Infect Dis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijid.2015.07.003","article-title":"Safety and immunogenicity of an investigational meningococcal Acwy Conjugate Vaccine (Menacwy-Crm) in healthy indian subjects aged 2 to 75 years","volume":"38","author":"Lalwani","year":"2015","journal-title":"Int J Infect Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (Pcv20) in adults 60 to 64 years of age","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/21645515.2018.1533777","article-title":"Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial","volume":"15","author":"Thompson","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1080\/21645515.2018.1455476","article-title":"Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: a randomized, open-label, non-inferiority trial","volume":"14","author":"Nakashima","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B87","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.1016\/j.vaccine.2021.08.038","article-title":"Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential Ppsv23 vaccination in healthy adults aged \u226550 years: a randomized phase Iii trial (Pneu-Path)","volume":"39","author":"Song","year":"2021","journal-title":"Vaccine."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1080\/21645515.2021.1888621","article-title":"Sequential administration of Prevnar 13\u2122 and Pneumovax\u2122 23 in healthy participants 50 years of age and older","volume":"17","author":"Buchwald","year":"2021","journal-title":"Hum Vaccin Immunother."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.1976581","article-title":"Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged \u226550 years: a randomized phase 3 trial (Pneu-Flu)","volume":"202","author":"Severance","year":"2021","journal-title":"Hum Vac Immunotherapeut."},{"key":"B90","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1128\/CVI.00711-14","article-title":"Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults \u2265 50 years of age in Mexico","volume":"22","author":"Tinoco","year":"2015","journal-title":"Clin Vaccine Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/21645515.2018.1509648","article-title":"A Phase Iii clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (Ppv23) in healthy children, adults, and elderly","volume":"15","author":"Huang","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1080\/21645515.2016.1165373","article-title":"Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects","volume":"12","author":"Ciprero","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1080\/21645515.2017.1331796","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: an open-label trial","volume":"13","author":"Solanki","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.4161\/hv.28633","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy japanese adults aged \u226550 years","volume":"10","author":"Shiramoto","year":"2014","journal-title":"Hum Vaccin Immunother."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1186\/s12879-018-3479-9","article-title":"Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in \u2265 50-year-old adults","volume":"18","author":"Song","year":"2018","journal-title":"BMC Infect Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, Hbsag-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1016\/j.vaccine.2012.01.087","article-title":"Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18\u201355 years of age","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.4161\/hv.7.12.18333","article-title":"Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults \u226550 years","volume":"7","author":"Gilbert","year":"2011","journal-title":"Hum Vaccin."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1080\/21645515.2018.1452578","article-title":"Immunogenicity, safety, and tolerability of a recombinant hepatitis B vaccine manufactured by a modified process in Healthy Young Japanese adults","volume":"14","author":"Kishino","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e0201236","DOI":"10.1371\/journal.pone.0201236","article-title":"Treatment of chronic hepatitis B na\u00efve patients with a therapeutic vaccine containing Hbs and Hbc antigens (a randomized, open and treatment controlled phase Iii clinical trial)","volume":"13","author":"Al Mahtab","year":"2018","journal-title":"PLoS ONE."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/infdis\/jis619","article-title":"Safety and immunogenicity of human papillomavirus-16\/18 As04-adjuvanted vaccine: a randomized trial in 10-25-year-old Hiv-seronegative African girls and young women","volume":"207","author":"Sow","year":"2013","journal-title":"J Infect Dis."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial","volume":"373","author":"Mu\u00f1oz","year":"2009","journal-title":"Lancet."},{"key":"B105","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent Hpv (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer."},{"key":"B106","doi-asserted-by":"publisher","first-page":"e83431","DOI":"10.1371\/journal.pone.0083431","article-title":"Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil\u2122 in adult women","volume":"8","author":"Luna","year":"2013","journal-title":"PLoS ONE."},{"key":"B107","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1128\/CVI.00002-12","article-title":"Mother-infant transfer of anti-human papillomavirus (Hpv) antibodies following vaccination with the quadrivalent Hpv (type 6\/11\/16\/18) virus-like particle vaccine","volume":"19","author":"Matys","year":"2012","journal-title":"Clin Vaccine Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (Hpv)-16\/18 As04-adjuvanted vaccine and Hpv-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a phase Iii randomized trial","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum Vaccin Immunother."},{"key":"B109","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1128\/CVI.00591-14","article-title":"Efficacy of human papillomavirus 16 and 18 (Hpv-16\/18) As04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind patricia trial","volume":"22","author":"Apter","year":"2015","journal-title":"Clin Vaccine Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (Hpv)-6\/11\/16\/18 vaccine on all Hpv-associated genital diseases in young women","volume":"102","author":"Mu\u00f1oz","year":"2010","journal-title":"J Natl Cancer Inst."},{"key":"B111","doi-asserted-by":"publisher","first-page":"100353","DOI":"10.1016\/j.eclinm.2020.100353","article-title":"Immunogenicity and safety of the As04-Hpv-16\/18 and Hpv-6\/11\/16\/18 human papillomavirus vaccines in asymptomatic young women living with Hiv aged 15-25 years: a phase Iv randomized comparative study","volume":"23","author":"Folschweiller","year":"2020","journal-title":"EClinicalMedicine."},{"key":"B112","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1002\/cam4.2399","article-title":"Efficacy, immunogenicity and safety of the As04-Hpv-16\/18 vaccine in Chinese women aged 18-25 years: end-of-study results from a phase Ii\/Iii, randomised, controlled trial","volume":"8","author":"Zhu","year":"2019","journal-title":"Cancer Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 As04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled viviane study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"B114","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/1471-0528.13070","article-title":"Persistence of immune responses to the Hpv-16\/18 As04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study","volume":"122","author":"Schwarz","year":"2015","journal-title":"Bjog."},{"key":"B115","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.vaccine.2018.12.030","article-title":"Safety of a quadrivalent human papillomavirus vaccine in a phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up","volume":"37","author":"Chen","year":"2019","journal-title":"Vaccine."},{"key":"B116","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1016\/j.vaccine.2015.06.088","article-title":"Immunogenicity and safety of the 9-valent Hpv vaccine in men","volume":"33","author":"Castellsagu\u00e9","year":"2015","journal-title":"Vaccine."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6\/11\/16\/18 vaccine: a combined analysis of five randomized controlled trials","volume":"114","author":"Garland","year":"2009","journal-title":"Obstet Gynecol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.vaccine.2019.01.069","article-title":"Efficacy, safety, and immunogenicity of a quadrivalent Hpv vaccine in japanese men: a randomized, phase 3, placebo-controlled study","volume":"37","author":"Mikamo","year":"2019","journal-title":"Vaccine."},{"key":"B119","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/21645515.2018.1528831","article-title":"Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination","volume":"15","author":"Burman","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"B120","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/1469-0691.12647","article-title":"Neisseria meningitidis; clones, carriage, and disease","volume":"20","author":"Read","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"B122","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1179\/2047773214Y.0000000126","article-title":"Global practices of meningococcal vaccine use and impact on invasive disease","volume":"108","author":"Ali","year":"2014","journal-title":"Pathog Glob Health."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current epidemiology and trends in meningococcal disease\u2014United States, 1996\u20132015","volume":"66","author":"MacNeil","year":"2017","journal-title":"Clin Infect Dis."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/S1473-3099(15)00217-0","article-title":"Global incidence of serogroup B invasive meningococcal disease: a systematic review","volume":"15","author":"Sridhar","year":"2015","journal-title":"Lancet Infect Dis."},{"key":"B125","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1574-6976.2006.00060.x","article-title":"A surveillance network for meningococcal disease in Europe","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev."},{"key":"B126","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"20581","DOI":"10.2807\/1560-7917.ES2013.18.37.20581","article-title":"Laboratory-confirmed invasive meningococcal disease: effect of the Hajj Vaccination Policy, Saudi Arabia, 1995 to 2011","volume":"18","author":"Memish","year":"2013","journal-title":"Euro Surveill."},{"key":"B128","unstructured":"2019"},{"key":"B129","unstructured":"2020"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e868","DOI":"10.1016\/j.ijid.2010.03.017","article-title":"Safety and immunogenicity of an investigational quadrivalent meningococcal Crm(197) conjugate vaccine, Menacwy-Crm, compared with licensed vaccines in adults in Latin America","volume":"14","author":"Stamboulian","year":"2010","journal-title":"Int J Infect Dis."},{"key":"B131","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1128\/CVI.00436-09","article-title":"Randomized trial on the safety, tolerability, and immunogenicity of Menacwy-Crm, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults","volume":"17","author":"Gasparini","year":"2010","journal-title":"Clin Vaccine Immunol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A Phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent Rlp2086 vaccine in healthy adults","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine."},{"key":"B134","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jpids\/piv064","article-title":"Immunogenicity, safety, and tolerability of bivalent Rlp2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc."},{"key":"B135","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1080\/21645515.2018.1532249","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (Pcv-15) compared to Pcv-13 in healthy older adults","volume":"15","author":"Stacey","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"B136","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1016\/j.vaccine.2018.03.012","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-na\u00efve adults \u226550 years of age","volume":"36","author":"Ermlich","year":"2018","journal-title":"Vaccine."},{"key":"B137","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.vaccine.2014.02.002","article-title":"Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-na\u00efve adults 60-64 years of age","volume":"32","author":"Greenberg","year":"2014","journal-title":"Vaccine."},{"key":"B139","doi-asserted-by":"publisher","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"Morb Mortal Wkly Rep"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100576","article-title":"Immunogenicity of pneumococcal vaccination in Hiv infected individuals: a systematic review and meta-analysis","author":"Garrido","year":"2020","journal-title":"EClinicalMedicine."},{"key":"B141","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.4161\/hv.32247","article-title":"Pneumococcal vaccination among Hiv-infected adult patients in the era of combination antiretroviral therapy","volume":"10","author":"Lee","year":"2014","journal-title":"Hum Vaccin Immunother."},{"key":"B142","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1128\/JCM.05476-11","article-title":"Haemophilus influenzae infections in the H. influenzae Type B conjugate vaccine","volume":"49","author":"Agrawal","year":"2011","journal-title":"Era J Clin Microbiol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1128\/CMR.00040-06","article-title":"Antimicrobial resistance in haemophilus influenzae","volume":"20","author":"Tristram","year":"2007","journal-title":"Clin Microbiol Rev."},{"volume-title":"Haemophilus Influenzae","year":"2021","author":"Khattak","key":"B144"},{"key":"B145","doi-asserted-by":"publisher","first-page":"26","DOI":"10.15172\/pneu.2015.6\/520","article-title":"A review of the role of haemophilus influenzae in community-acquired pneumonia","volume":"6","author":"Slack","year":"2015","journal-title":"Pneumonia."},{"key":"B146","doi-asserted-by":"publisher","first-page":"7203587","DOI":"10.1155\/2016\/7203587","article-title":"Hib vaccines: past, present, and future perspectives","volume":"2016","author":"Zarei","year":"2016","journal-title":"J Immunol Res."},{"key":"B147","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1365-2567.2004.01971.x","article-title":"Haemophilus influenzae type B conjugate vaccines","volume":"113","author":"Kelly","year":"2004","journal-title":"Immunology."},{"key":"B148","doi-asserted-by":"publisher","first-page":"ofc044","DOI":"10.1093\/ofid\/ofu044","article-title":"Invasive haemophilus influenzae disease in adults \u226565 years, United States, 2011","volume":"1","author":"Blain","year":"2014","journal-title":"Open For Infect Dis."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3201\/eid1709.101991","article-title":"Increasing incidence of invasive haemophilus influenzae disease in adults, Utah, USA","volume":"17","author":"Rubach","year":"2011","journal-title":"Emerg Infect Dis."},{"key":"B150","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1016\/j.vaccine.2019.07.100","article-title":"Non-typeable haemophilus influenzae protein vaccine in adults with copd: a phase 2 clinical trial","volume":"37","author":"Wilkinson","year":"2019","journal-title":"Vaccine."},{"key":"B151","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1016\/j.vaccine.2019.04.041","article-title":"Safety and immunogenicity of non-typeable haemophilus influenzae-moraxella catarrhalis vaccine","volume":"37","author":"Van Damme","year":"2019","journal-title":"Vaccine."},{"key":"B152","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1128\/CVI.00430-13","article-title":"Safety, immunogenicity, and antibody persistence following an investigational streptococcus pneumoniae and haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults","volume":"21","author":"Berglund","year":"2014","journal-title":"Clin Vaccine Immunol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.puhe.2016.08.007","article-title":"Response to anti-Hbv vaccine and 10-year follow-up of antibody levels in healthcare workers","volume":"139","author":"La Fauci","year":"2016","journal-title":"Public Health."},{"key":"B154","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/jama.1986.03380070075022","article-title":"The safety of the hepatitis B vaccine. Inactivation of the aids virus during routine vaccine manufacture","volume":"256","author":"Francis","year":"1986","journal-title":"J Am Med Assoc."},{"key":"B155","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J Infect Dis."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2165\/00003495-200363100-00006","article-title":"Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B","volume":"63","author":"Keating","year":"2003","journal-title":"Drugs."},{"key":"B157","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (Hbsag-1018) compared to a licensed hepatitis B vaccine in healthy adults 40\u201370 years of age","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine."},{"key":"B158","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1016\/j.vaccine.2013.05.067","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (Hbsag-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease","volume":"31","author":"Janssen","year":"2013","journal-title":"Vaccine."},{"key":"B159","doi-asserted-by":"publisher","first-page":"578","DOI":"10.4161\/hv.6.7.11883","article-title":"Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (Hb-As02v) in healthy adults","volume":"6","author":"Beran","year":"2010","journal-title":"Hum Vaccin."},{"key":"B160","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.aohep.2019.03.012","article-title":"Evaluation of response to hepatitis B virus vaccine in adults with human immunodeficiency virus","volume":"18","author":"Rech-Medeiros","year":"2019","journal-title":"Ann Hepatol."},{"volume-title":"Human Papillomavirus","year":"2021","author":"Luria","key":"B161"},{"key":"B162","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.ygyno.2008.07.045","article-title":"Natural history and epidemiology of Hpv infection and cervical cancer","volume":"110","author":"Castellsague","year":"2008","journal-title":"Gynecol Oncol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices","volume":"68","author":"Meites","year":"2019","journal-title":"Morb Mortal Wkly Rep."},{"key":"B164","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/sextrans-2012-050685","article-title":"High prevalence and incidence of human papillomavirus in a cohort of healthy young african female subjects","volume":"89","author":"Watson-Jones","year":"2013","journal-title":"Sex Transm Infect."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(20)30524-6","article-title":"Efficacy of the bivalent Hpv vaccine against Hpv 16\/18-associated precancer: long-term follow-up results from the costa rica vaccine trial","volume":"21","author":"Porras","year":"2020","journal-title":"Lancet Oncol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of Hpv-16\/18 As04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind patricia trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"Dillner","year":"2010","journal-title":"BMJ."},{"key":"B168","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/cid\/cix797","article-title":"A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries","volume":"66","author":"Kjaer","year":"2018","journal-title":"Clin Infect Dis."},{"key":"B169","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet."},{"key":"B170","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/21645515.2020.1839292","article-title":"Long-term effectiveness of the nine-valent human papillomavirus vaccine in scandinavian women: interim analysis after 8 years of follow-up","volume":"17","author":"Kjaer","year":"2021","journal-title":"Hum Vaccin Immunother."},{"key":"B171","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ygyno.2019.03.253","article-title":"Nine-valent Hpv vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population","volume":"154","author":"Giuliano","year":"2019","journal-title":"Gynecol Oncol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/infdis\/jiy133","article-title":"Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian Countries","volume":"218","author":"Garland","year":"2018","journal-title":"J Infect Dis."},{"key":"B173","unstructured":"Vaccines against influenza who position paper\u2014November 201246176Weekly Epidemiol Rec.872012"},{"key":"B174","unstructured":"2018"},{"key":"B175","unstructured":"2021"},{"key":"B176","doi-asserted-by":"publisher","first-page":"10034","DOI":"10.3390\/vaccines8010034","article-title":"Vaccination programs for adults in Europe, 2019","volume":"8","author":"Cassimos","year":"2020","journal-title":"Vaccines."},{"key":"B177","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the advisory committee on immunization practices (Acip)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"Morb Mortal Wkly Rep."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: updated recommendations of the advisory committee on immunization practices","volume":"68","author":"Matanock","year":"2019","journal-title":"Morb Mortal Wkly Rep."},{"key":"B179","unstructured":"2020"},{"key":"B180","unstructured":"2010"},{"key":"B181","unstructured":"2018"},{"key":"B182","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijid.2015.09.019","article-title":"Invasive pneumococcal disease among children younger than 5 years of age before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco","volume":"40","author":"Diawara","year":"2015","journal-title":"Int J Infect Dis."},{"key":"B183","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40121-018-0226-x","article-title":"Cost-effectiveness of the pneumococcal conjugate vaccine (10- or 13-valent) versus no vaccination for a national immunization program in Tunisia or Algeria","volume":"8","author":"Pugh","year":"2019","journal-title":"Infect Dis Ther."},{"key":"B184","unstructured":"2013"},{"key":"B185","unstructured":"2016"},{"key":"B186","unstructured":"Programme \u00e9largie de vaccination aux pays du Maghreb. Etude de cas de la Tunisie. Revue syst\u00e9matique de la literature696705\n            KacemM\n            DhouibW\n            BennasrallahC\n            ZemniI\n            AbrougH\n            FredjMB\n          La Tunise Medicale962018"},{"key":"B187","unstructured":"2014"},{"key":"B188","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/occmed\/kqn071","article-title":"Hepatitis B in Moroccan health care workers","volume":"58","author":"Djeriri","year":"2008","journal-title":"Occup Med."},{"key":"B189","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1016\/j.vaccine.2018.08.038","article-title":"Observational study of vaccine effectiveness 20 years after the introduction of universal hepatitis B vaccination in Tunisia","volume":"36","author":"Ben Hadj","year":"2018","journal-title":"Vaccine."},{"key":"B190","unstructured":"2020"},{"key":"B191","unstructured":"2022"},{"key":"B192","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5001\/omj.2018.54","article-title":"A snapshot of influenza surveillance, vaccine recommendations, and vaccine access, drivers, and barriers in selected Middle Eastern and North African Countries","volume":"33","author":"Al Awaidy","year":"2018","journal-title":"Oman Med J."},{"key":"B193","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jiph.2018.10.009","article-title":"Review of seasonal influenza vaccination in the eastern mediterranean region: policies, use and barriers","volume":"12","author":"Zaraket","year":"2019","journal-title":"J Infect Public Health."},{"key":"B194","unstructured":"2015"},{"key":"B195","unstructured":"2022"},{"key":"B196","unstructured":"2012"},{"key":"B197","unstructured":"2021"},{"key":"B198","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/21645515.2017.1412020","article-title":"Vaccine prevention of meningococcal disease in Africa: major advances, remaining challenges","volume":"14","author":"Mustapha","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B199","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1377\/hlthaff.2016.0462","article-title":"Modeling the economic burden of adult vaccine-preventable diseases in the United States","volume":"35","author":"Ozawa","year":"2016","journal-title":"Health Aff."},{"key":"B200","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/21645515.2020.1780847","article-title":"Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States","volume":"17","author":"Talbird","year":"2021","journal-title":"Hum Vaccin Immunother."},{"key":"B201","doi-asserted-by":"publisher","first-page":"e0149540","DOI":"10.1371\/journal.pone.0149540","article-title":"Cost-effectiveness of vaccinating immunocompetent \u226565 year olds with the 13-valent pneumococcal conjugate vaccine in England","volume":"11","author":"Van Hoek","year":"2016","journal-title":"PLoS ONE."},{"key":"B202","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1016\/j.vaccine.2014.05.015","article-title":"Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel","volume":"32","author":"Yamin","year":"2014","journal-title":"Vaccine."},{"key":"B203","doi-asserted-by":"publisher","first-page":"A607","DOI":"10.1016\/j.jval.2014.08.2122","article-title":"Modeled outcomes and overall costs of the 13-valent pneumococcal conjugate vaccine in the Tunisian National Vaccination Program","volume":"17","author":"Zigmond","year":"2014","journal-title":"Value Health."},{"key":"B204","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.inhe.2011.08.004","article-title":"Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries","volume":"3","author":"Nakamura","year":"2011","journal-title":"Int Health."},{"key":"B205","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40273-016-0451-7","article-title":"Challenges in cost-effectiveness analysis modelling of Hpv vaccines in low- and middle-income countries: a systematic review and practice recommendations","volume":"35","author":"Ekwunife","year":"2017","journal-title":"Pharmacoeconomics."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.903376\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T07:21:55Z","timestamp":1656660115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.903376\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":205,"alternative-id":["10.3389\/fpubh.2022.903376"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.903376","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"article-number":"903376"}}